bedoradrine
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00679263)
Timeline
Indications
Mechanism of action
- Beta-2 adrenergic receptorAGONIST
ADRB2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)C(=O)COc1ccc2c(c1)C[C@@H](NC[C@H](O)c1ccc(O)c(CCO)c1)CC2- Mol. weight
- 428.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111083 ↗
- ChEMBLCHEMBL2218893 ↗
Also known as
- bedoradrine
- bedoradrine
- bedoradrine
- bedoradrine sulfate
- bedoradrine sulfate
- bedoradrine sulfate
- kur-1246
- kur-1246
- kur-1246
- mn-221
- mn-221
- mn-221
- mn-221
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01551316 | Phase 1 | Mar 1, 2012 | MediciNova |
| NCT01013142 | Phase 1 | Nov 1, 2009 | MediciNova |
| NCT00838591 | Phase 2 | Mar 1, 2009 | MediciNova |
| NCT00683449 | Phase 2 | Jun 1, 2008 | MediciNova |
| NCT00679263 | Phase 2 | Feb 1, 2008 | MediciNova |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MediciNova | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1